155 results match your criteria Prostate Cancer - Brachytherapy Radioactive Seed Implantation Therapy


Expert consensus on computed tomography-assisted three-dimensional-printed coplanar template guidance for interstitial permanent radioactive I seed implantation therapy.

J Cancer Res Ther 2019 ;15(7):1430-1434

Department of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.

Interstitial permanent radioactive seed implantation delivers a high local dose to tumors and sharply drops off at surrounding normal tissues. Radioactive seeds implanted via ultrasound or computed tomography (CT) guidance are minimally invasive and facilitate quick recovery. Transrectal ultrasound-guided I seed implantation assisted by a transperineal plane template is standard for early-stage prostate carcinoma, with a highly consistent target volume dose distribution. Read More

View Article and Full-Text PDF

A mixed-integer linear programming optimization model framework for capturing expert planning style in low dose rate prostate brachytherapy.

Phys Med Biol 2019 03 27;64(7):075007. Epub 2019 Mar 27.

Department of Mechanical Engineering, 10-237 Donadeo Innovation Centre for Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.

Low dose rate (LDR) brachytherapy is a minimally invasive form of radiation therapy, used to treat prostate cancer, and it involves permanent implantation of radioactive sources (seeds) inside of the prostate gland. Treatment planning in brachytherapy involves a decision making process for the placement of the sources in order to deliver an effective dose of radiation to cancerous tissue in the prostate while sparing the surrounding healthy tissue. Such a decision making process can be modeled as a mixed-integer linear programming (MILP) problem. Read More

View Article and Full-Text PDF

Reduction of seed motion using a bio-absorbable polymer coating during permanent prostate brachytherapy using a mick applicator technique.

J Appl Clin Med Phys 2018 May 17;19(3):44-51. Epub 2018 Apr 17.

Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Purpose: The addition of a braided bio-absorbable vicryl coating to the surface of radioactive seeds used for low dose rate (LDR) prostate brachytherapy is intended to reduce the incidence of seed movement and migration. Here, we present a single-institution study of the frequency and severity of seed slippage (initial seed movement) of coated seeds in comparison with uncoated seeds.

Methods: Forty-seven patients received permanent prostate brachytherapy, with either coated (n = 26) or uncoated (n = 21) seeds. Read More

View Article and Full-Text PDF

Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.

Brachytherapy 2018 Mar - Apr;17(2):265-276. Epub 2017 Dec 18.

Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Purpose: To compare quality of life (QoL) after brachytherapy with one of the three approved radioactive isotopes.

Methods And Materials: Patients with mostly favorable intermediate-risk prostate cancer were treated on this prospective phase II trial with brachytherapy as monotherapy, without hormonal therapy. QoL was recorded at baseline and each follow-up by using the Expanded Prostate Cancer Index Composite instrument. Read More

View Article and Full-Text PDF
January 2019

Expert consensus workshop report: Guideline for three-dimensional printing template-assisted computed tomography-guided I seeds interstitial implantation brachytherapy.

J Cancer Res Ther 2017 ;13(4):607-612

Department of Radiation Oncology, Peking University Third Hospital, Beijing; Chinese North Multi Center Cooperative Group of Particles Radiotherapy Specialized of Beijing Medical Association, Beijing, China.

Radioactive 125I seeds (RIS) interstitial implantation brachytherapy has been a first-line treatment for early-stage cancer of the prostate gland. However, its poor accuracy and homogeneity has limited its indication and hampered its popularization for a long time. Intriguingly, scholars based in China introduced computed tomography (CT)-guided technology to improve the accuracy and homogeneity of RIS implantation and broadened the indications. Read More

View Article and Full-Text PDF

Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues.

J Nucl Med 2017 09 13;58(9):1380-1385. Epub 2017 Apr 13.

Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Brachytherapy is a type of radiotherapy wherein titanium capsules containing therapeutic radioisotopes are implanted within tumor tissues, enabling high-dose radioirradiation to tumor tissues around the seeds. Although marked therapeutic effects have been demonstrated, brachytherapy needs a complicated implantation technique under general anesthesia and the seeds could migrate to other organs. The aim of this study was to establish a novel brachytherapy using biocompatible, injectable thermoresponsive polymers (polyoxazoline [POZ]) labeled with Y, which can self-aggregate above a specific transition temperature (Tt), resulting in long-term intratumoral retention of radioactivity and therapeutic effect. Read More

View Article and Full-Text PDF
September 2017

Low-Dose Prostate Cancer Brachytherapy with Radioactive Palladium-Gold Nanoparticles.

Adv Healthc Mater 2017 Feb 24;6(4). Epub 2017 Jan 24.

Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval (CR CHU de Québec), axe Médecine Régénératrice, Québec, QC, G1L 3L5, Canada.

Prostate cancer (PCa) is one of the leading causes of death among men. Low-dose brachytherapy is an increasingly used treatment for PCa, which requires the implantation of tens of radioactive seeds. This treatment causes discomfort; these implants cannot be removed, and they generate image artifacts. Read More

View Article and Full-Text PDF
February 2017

Lessons Learned from Autopsying an Unidentified Body with Iodine-125 Seeds Implanted for Prostate Brachytherapy.

J Forensic Sci 2017 Mar 22;62(2):536-540. Epub 2016 Nov 22.

Department of Forensic Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.

We report here lessons learned from an autopsy case involving radioactive materials. We performed an autopsy of an unidentified mummified man with no available medical history whom from imaging findings we suspected had received radioactive seed implants for prostate brachytherapy. We returned the excised prostate and seeds to the body. Read More

View Article and Full-Text PDF

Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapy.

Brachytherapy 2016 May-Jun;15(3):266-273. Epub 2016 Apr 20.

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address:

Purpose: To report the long-term control and toxicity outcomes of patients with clinically localized prostate cancer, who underwent low-dose-rate prostate brachytherapy with magnetic resonance spectroscopic image (MRSI)-directed dose escalation to intraprostatic regions.

Methods And Materials: Forty-seven consecutive patients between May 2000 and December 2003 were analyzed retrospectively. Each patient underwent a preprocedural MRSI, and MRS-positive voxels suspicious for malignancy were identified. Read More

View Article and Full-Text PDF

Learning-Based Multi-Label Segmentation of Transrectal Ultrasound Images for Prostate Brachytherapy.

IEEE Trans Med Imaging 2016 Mar 20;35(3):921-32. Epub 2015 Nov 20.

Low-dose-rate prostate brachytherapy treatment takes place by implantation of small radioactive seeds in and sometimes adjacent to the prostate gland. A patient specific target anatomy for seed placement is usually determined by contouring a set of collected transrectal ultrasound images prior to implantation. Standard-of-care in prostate brachytherapy is to delineate the clinical target anatomy, which closely follows the real prostate boundary. Read More

View Article and Full-Text PDF

A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.

Prostate Cancer Prostatic Dis 2015 Jun 17;18(2):96-103. Epub 2015 Feb 17.

1] Department of Radiation Oncology, Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA [2] Department of Radiation Oncology Service, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA, USA.

Permanent radioactive seed implantation provides highly effective treatment for prostate cancer that typically includes multidisciplinary collaboration between urologists and radiation oncologists. Low dose-rate (LDR) prostate brachytherapy offers excellent tumor control rates and has equivalent rates of rectal toxicity when compared with external beam radiotherapy. Owing to its proximity to the anterior rectal wall, a small portion of the rectum is often exposed to high doses of ionizing radiation from this procedure. Read More

View Article and Full-Text PDF

AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: report of Task Group 192.

Med Phys 2014 Oct;41(10):101501

Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.

In the last decade, there have been significant developments into integration of robots and automation tools with brachytherapy delivery systems. These systems aim to improve the current paradigm by executing higher precision and accuracy in seed placement, improving calculation of optimal seed locations, minimizing surgical trauma, and reducing radiation exposure to medical staff. Most of the applications of this technology have been in the implantation of seeds in patients with early-stage prostate cancer. Read More

View Article and Full-Text PDF
October 2014

Postmortem radiation safety and issues pertaining to permanent prostate seed implantation in Japan.

Brachytherapy 2015 Mar-Apr;14(2):136-41. Epub 2014 Sep 6.

Working Group for Promotion of Permanent Seed Implantation Therapy of Prostate Cancer, Subcommittee of Brachytherapy, Medical Science and Pharmaceutical Committee, Japan Radioisotope Association, Tokyo, Japan; Department of Radiology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Purpose: If a prostate cancer patient treated with (125)I brachytherapy dies within 12 months after the treatment, prostate removal before cremation is recommended to avoid problems related to radioactivity in the ashes, such as inhalation of airborne particulate matter by crematorium staff or nearby residents. To provide guidance for such cases, a manual prepared under the editorial supervision of several professional associations was issued in 2008 in Japan. Herein, we investigated the incidence and causes of death, and the actions taken subsequent to death, among prostate cancer patients who died within 12 months after (125)I brachytherapy over a 10-year period in Japan; and we compared the results before and after the manual was issued. Read More

View Article and Full-Text PDF
September 2015

Bioevaluation of (125) I Ocu-Prosta seeds for application in prostate cancer brachytherapy.

Indian J Med Res 2014 Apr;139(4):555-60

Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.

Background & Objectives: In recent years, brachytherapy involving permanent radioactive seed implantation has emerged as an effective modality for the management of cancer of prostate. 125 I-Ocu-Prosta seeds were indigenously developed and studies were carried out to assess the safety of the indigenously developed 125 I-Ocu-Prosta seeds for treatment of prostate cancer.

Methods: Animal experiments were performed to assess the likelihood of in vivo release of 125 I from radioactive seeds and migration of seeds implanted in the prostate gland of the rabbit. Read More

View Article and Full-Text PDF

MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy.

Phys Med Biol 2014 May 28;59(10):2505-16. Epub 2014 Apr 28.

The University of Texas at Houston Graduate School of Biomedical Sciences, 6767 Bertner Avenue, Houston, TX 77030, USA. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Brachytherapy, a radiotherapy technique for treating prostate cancer, involves the implantation of numerous radioactive seeds into the prostate. While the implanted seeds can be easily identified on a computed tomography image, distinguishing the prostate and surrounding soft tissues is not as straightforward. Magnetic resonance imaging (MRI) offers superior anatomical delineation, but the seeds appear as dark voids and are difficult to identify, thus creating a conundrum. Read More

View Article and Full-Text PDF

Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

Expert Rev Anticancer Ther 2014 Jan;14(1):39-50

Department of Radiation Oncology Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Low-dose rate brachytherapy (LDR-BT), involving implantation of radioactive seeds into the prostate, is an established monotherapy for most low-risk and select intermediate- and high-risk prostate cancer patients. High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT from a radiobiological and radiophysics perspective, to the patient himself, and in terms of resource allocation. Studies of HDR-BT monotherapy have encouraging results in terms of biochemical control, patient survival, treatment toxicity and erectile preservation. Read More

View Article and Full-Text PDF
January 2014

Evaluation of dosimetry and excess seeds in permanent brachytherapy using a modified hybrid method: a single-institution experience.

J Radiat Res 2013 May 4;54(3):479-84. Epub 2013 Jan 4.

Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.

Permanent prostate brachytherapy is frequently performed worldwide, and many studies have demonstrated its favorable outcomes. Implant seeds used in this procedure contain a precise amount of radionuclide and are completely sealed. Because these seeds are not manufactured in Japan, they are expensive (6300 yen per seed) and therefore need careful management as a radioisotope. Read More

View Article and Full-Text PDF

Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ.

Cancer Res 2012 Nov;72(22):5956-65

Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA.

Brachytherapy is a common clinical technique involving implantation of sealed radioactive "seeds" within a tumor to selectively irradiate the tumor mass while minimizing systemic toxicity. To mitigate the disadvantages associated with complex surgical implantation and subsequent device removal procedures, we have developed an alternative approach using a genetically encoded peptide polymer solution composed of a thermally responsive elastin-like polypeptide (ELP) radiolabeled with (131)I that self-assembles into radionuclide seeds upon intratumoral injection. The formation of these nontoxic and biodegradable polymer seeds led to prolonged intratumoral retention (~85% ID/tumor 7 days postinjection) of the radionuclide, elicited a tumor growth delay in 100% of the tumors in two human xenografts (FaDu and PC-3), and cured more than 67% of tumor-bearing animals after a single administration of labeled ELP. Read More

View Article and Full-Text PDF
November 2012

Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose (125)I seeds.

Keio J Med 2012 ;61(3):89-94

Department of Radiology, School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan.

The dose received by 90% of the prostate volume (D90) is the key parameter of dosimetric analysis in prostate brachytherapy. The aim of this analysis was to identify preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose (125)I seeds. We reviewed the records of 210 patients who underwent transperineal interstitial prostate brachytherapy with loose (125)I seeds for clinical T1/T2 prostate cancer at our institution. Read More

View Article and Full-Text PDF
February 2013

Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer.

J Radiol Prot 2012 Sep 2;32(3):339-47. Epub 2012 Aug 2.

Department of Medical Physics, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.

Treatment of low grade prostate cancer with permanent implant of radioactive seeds has become one of the most common brachytherapy procedures in use today. The implant procedure is usually performed with fluoroscopy image guidance to ensure that the seeds are deployed in the planned locations. In this situation the physician performing the transperineal implant is required to be close to the fluoroscopy unit and dose to the eye lens may be of concern. Read More

View Article and Full-Text PDF
September 2012

³²P-chromic phosphate-Poly(L-Lactide) seeds of sustained release and their brachytherapy for prostate cancer with lymphatic metastasis.

Cancer Biother Radiopharm 2012 Sep 26;27(7):446-51. Epub 2012 Jul 26.

Department of Urology, Yangzhou First Hospital Affiliated to Southeast University, Yangzhou, China.

This study aims to develop a new agent, the ³²P-chromic phosphate-poly(l-lactide) (³²P-CP-PLLA) seed and to explore its anticancer effect against prostate cancer (Pca) with local lymphatic metastasis in nude mice. ³²P-CP-PLLA seeds of sustained release and nude mouse models of Pca with lymphatic metastasis were prepared. After 4 weeks, the tumor nude mouse models were randomly assigned into five groups. Read More

View Article and Full-Text PDF
September 2012

Ultrasound-fluoroscopy registration for prostate brachytherapy dosimetry.

Med Image Anal 2012 Oct 16;16(7):1347-58. Epub 2012 Jun 16.

Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, USA.

Prostate brachytherapy is a treatment for prostate cancer using radioactive seeds that are permanently implanted in the prostate. The treatment success depends on adequate coverage of the target gland with a therapeutic dose, while sparing the surrounding tissue. Since seed implantation is performed under transrectal ultrasound (TRUS) imaging, intraoperative localization of the seeds in ultrasound can provide physicians with dynamic dose assessment and plan modification. Read More

View Article and Full-Text PDF
October 2012

Real-time photoacoustic imaging of prostate brachytherapy seeds using a clinical ultrasound system.

J Biomed Opt 2012 Jun;17(6):066005

Johns Hopkins University, Department of Biomedical Engineering, 3400 North Charles Street, Baltimore, Maryland 21218, USA.

Prostate brachytherapy is a popular prostate cancer treatment option that involves the permanent implantation of radioactive seeds into the prostate. However, contemporary brachytherapy procedure is limited by the lack of an imaging system that can provide real-time seed-position feedback. While many other imaging systems have been proposed, photoacoustic imaging has emerged as a potential ideal modality to address this need, since it could easily be incorporated into the current ultrasound system used in the operating room. Read More

View Article and Full-Text PDF

Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy.

Med Dosim 2012 3;37(4):387-90. Epub 2012 May 3.

Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Advances in brachytherapy treatment planning systems have allowed the opportunity for brachytherapy to be planned intraoperatively as well as preoperatively. The relative advantages and disadvantages of each approach have been the subject of extensive debate, and some contend that the intraoperative approach is vital to the delivery of optimal therapy. The purpose of this study was to determine whether high-quality permanent prostate implants can be achieved consistently using a preoperative planning approach that allows for, but does not necessitate, intraoperative optimization. Read More

View Article and Full-Text PDF

Effects of insertion speed and trocar stiffness on the accuracy of needle position for brachytherapy.

Med Phys 2012 Apr;39(4):1811-7

Biomedical Engineering Department, University of Michigan, Ann Arbor, MI, USA.

Purpose: In prostate brachytherapy, accurate positioning of the needle tip to place radioactive seeds at its target site is critical for successful radiation treatment. During the procedure, needle deflection leads to seed misplacement and suboptimal radiation dose to cancerous cells. In practice, radiation oncologists commonly use high-speed hand needle insertion to minimize displacement of the prostate as well as the needle deflection. Read More

View Article and Full-Text PDF

Use of needle track detection to quantify the displacement of stranded seeds following prostate brachytherapy.

IEEE Trans Med Imaging 2012 Mar 6;31(3):738-48. Epub 2011 Dec 6.

Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, Canada.

We aim to compute the movement of permanent stranded implant brachytherapy radioactive sources (seeds) in the prostate from the planned seed distribution to the intraoperative fluoroscopic distribution, and then to the postimplant computed tomography (CT) distribution. We present a novel approach to matching the seeds in these distributions to the plan by grouping the seeds into needle tracks. First, we identify the implantation axis using a sample consensus algorithm. Read More

View Article and Full-Text PDF

Comparison of template-matching and singular-spectrum-analysis methods for imaging implanted brachytherapy seeds.

IEEE Trans Ultrason Ferroelectr Freq Control 2011 Nov;58(11):2484-91

Brachytherapy using small implanted radioactive seeds is becoming an increasingly popular method for treating prostate cancer, in which a radiation oncologist implants seeds in the prostate transperineally under ultrasound guidance. Dosimetry software determines the optimal placement of seeds for achieving the prescribed dose based on ultrasonic determination of the gland boundaries. However, because of prostate movement and distortion during the implantation procedure, some seeds may not be placed in the desired locations; this causes the delivered dose to differ from the prescribed dose. Read More

View Article and Full-Text PDF
November 2011

Brachytherapy for clinically localized prostate cancer: optimal patient selection.

Arch Esp Urol 2011 Oct;64(8):847-57

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

The objective of this review is to present an overview of each modality and delineate how to best select patients who are optimal candidates for these treatment approaches. Prostate brachytherapy as a curative modality for clinically localized prostate cancer has become increasingly utilized over the past decade; 25% of all early cancers are now treated this way in the United States (1). The popularity of this treatment strategy lies in the highly conformal nature of radiation dose, low morbidity, patient convenience, and high efficacy rates. Read More

View Article and Full-Text PDF
October 2011

Coregistered photoacoustic-ultrasound imaging applied to brachytherapy.

J Biomed Opt 2011 Aug;16(8):080502

Brachytherapy is a form of radiation therapy commonly used in the treatment of prostate cancer wherein sustained radiation doses can be precisely targeted to the tumor area by the implantation of small radioactive seeds around the treatment area. Ultrasound is a popular imaging mode for seed implantation, but the seeds are difficult to distinguish from the tissue structure. In this work, we demonstrate the feasibility of photoacoustic imaging for identifying brachytherapy seeds in a tissue phantom, comparing the received intensity to endogenous contrast. Read More

View Article and Full-Text PDF